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While efficient treatments for Alzheimer’s disease (AD) remain elusive, a growing body of 
research has highlighted sleep-wake regulation as a potential modifiable factor to delay 
disease progression. Evidence accumulated in recent years is pointing toward a tight link 
between sleep-wake disruption and the three main hallmarks of the pathogenesis of AD, i.e. 
abnormal amyloid-beta (Aβ) and tau proteins accumulation, and neurodegeneration. However, 
all three hallmarks are rarely considered together in the same study. In this review, we gather 
and discuss findings in favor of an association between sleep-wake disruption and each AD 
hallmarks in animal models and in humans, with a focus on the preclinical stages of the 
disease. We emphasize that these relationships are likely bidirectional for each of these 
hallmarks. Altogether, current findings provide strong support for considering sleep-wake 
disruption as a true risk factor in the early unfolding of AD, but more research integrating 
recent technical advances is needed, particularly with respect to tau protein and 
neurodegeneration. Interventional longitudinal studies among cognitively healthy older 
individuals should assess the practical use of improving sleep-wake regulation to slow down 
the progression of AD pathogenesis. 
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Statement of significance: Here, we integrate within a single review the findings associating 
sleep-wake regulation and the three main hallmarks of Alzheimer’s disease (AD) 
pathogenesis in the preclinical stages of the disease. The causality of these relationships is 
discussed and the emphasis is placed on the bidirectionality between sleep-wake quality and 




















sleep-wake disruption as a true risk factor in the early unfolding of AD, the practical use of 
improving sleep and wakefulness to hinder AD pathogenesis should be further investigated by 
researchers and clinicians. 
 
Introduction 
The current search for an Alzheimer’s disease (AD) treatment, although encouraging, 
is still failing to provide efficient therapies to significantly delay disease progression, and the 
existing ones only grant marginal symptomatic relief 
1
. Indeed, several recent clinical trials 
were unsuccessful in developing new drug therapies against AD 
2,3
. With an estimated health-
care cost of 818 billion US dollars per year worldwide, AD, the most prevalent form of 
dementia, represents an important socio-economic and scientific challenge in our ever-aging 
society 
4
. Some consider that delaying the onset of AD by just 5 years would decrease AD 
costs by 40% 
5
. Early detection and prevention are promising means to reach this objective 
6
. 
However, only 30% of AD cases are considered to be associated with recognized 
environmental risk factors for AD (diabetes, low education, smoking, lack of physical 
activity, hypertension, and depression) and acting on them would only moderately attenuate 
the foreseen increase in AD prevalence 
7
. Hence, identifying novel modifiable protective and 
risk factors for AD is crucially needed. These novel factors should facilitate the early 
detection of an increased risk for AD, even in asymptomatic individuals, and allow for more 
efficient prevention 
6
. In the present review paper, we argue that the regulation of the sleep-
wake cycle and its disruption constitute such novel factors. The last decade has indeed seen a 
growing body of evidence supporting the link between AD-related processes and the 
regulation of sleep and wakefulness 
8–12
. Accordingly, a recent meta-analysis of 27 




















attributed to treatable sleep problems, and that individuals with sleep-related issues exhibit a 
1.55 times higher risk of developing the disease 
13
.  
The main pathophysiological hallmarks of AD are the abnormal accumulation in the 
brain of amyloid-beta (Aβ) protein in plaques and of tau protein in neurofibrillary tangles 
(NFTs), together with neurodegeneration, i.e. synaptic and neuronal loss 
14
. These hallmarks 
contribute to predicting the conversion of mild cognitive impairment (MCI), a prodromal 
phase of AD, to fully declared AD 
15,16
. Importantly, it is now well established that Aβ and tau 
protein accumulations as well as brain atrophy start decades before MCI or AD symptoms 
onset. A period corresponding to AD ‘preclinical’ stages has therefore been proposed and 
encompasses the 10 to 20 years preceding observable cognitive impairments 
15,17
. It is 
important to stress that AD preclinical stages reflect an increased risk for the disease rather 
than being a deterministic feature: whether and when one will develop symptomatic AD 
cannot be established based solely on the presence of AD pathophysiological hallmarks. 
Nevertheless, together with Apolipoprotein E (APOE) polymorphism, the strongest genetic 
risk factor for sporadic AD 
18–20
, these pathophysiological changes offer the current best bases 
for applying prevention strategies to individuals at risk of developing sporadic AD.  
Here, we provide a narrative review of the evidence for the relationship between the 
disruption of the sleep-wake cycle and the hallmarks of AD (i.e. Aβ burden, tau burden, and 
neurodegeneration) during its preclinical stages, both in humans and animal models. The 
papers linking sleep-wake regulation and AD pathophysiology that were considered are 
summarized in an overview table for each hallmark, i.e. at the end of the Aβ section (Table 
1), of the tau section (Table 2), and of the neurodegeneration section (Table 3). We will only 




















compared with the early-onset familial form which accounts for less than 5% of AD cases 
21,22
.  
Sleep-wake regulation and amyloid-beta 
Aβ refers to peptides of 36-43 amino acids that normally exist in the brain in a soluble 
form but become toxic when aggregated into diffusible oligomers 
23
 and eventually form 
extracellular insoluble amyloid plaques 
24
. In non-pathological conditions, the physiological 
role of Aβ is uncertain but is suspected to participate to normal synaptic function 23. Aβ40 is 
the major Aβ species (~80-90%) produced by β- and γ-secretase in the sequential enzymatic 
cleavage of the larger transmembrane amyloid precursor protein (APP). Aβ42, one of the 
minor species (~5-10%), plays a crucial role in the aggregation of amyloid into plaques 
because of its hydrophobic and fibrillogenic properties 
25–27
. One can monitor AD 
pathophysiology progression with positron emission tomography (PET) using Aβ ligands, but 
Aβ42 assay in the cerebrospinal fluid (CSF) is also a sensitive and common biomarker for 
AD. In fact, lower CSF Aβ42 concentration is thought to reflect and even precede amyloid 
plaque formation in the brain 
28,29
. 
The AD-related pathophysiological process of Aβ follows a stereotyped progression 
pattern, with Aβ deposits first found in the neocortex. As the disease progresses, allocortical 
brain regions (e.g. entorhinal cortex, hippocampus) are involved as well as nuclei from the 
basal forebrain. Ultimately, Aβ burden encompasses brainstem nuclei and the cerebellum 30. 
The prevailing theory of AD pathogenesis hypothesizes that the accumulation of Aβ into 
insoluble plaques is the key initiator of a series of pathogenic processes that eventually lead to 
AD 
31,32
. At first, changes in Aβ levels caused by an increase in total Aβ production and/or a 
reduced clearance result in Aβ deposits that impede synaptic function and diminish long-term 




















amplify synaptic and neuronal damage, precipitating widespread neuronal dysfunction, cell 
death, and ultimately dementia with plaque and tangle pathology 
33
. Although the broad 
outlines of the so-called ‘amyloid cascade hypothesis’ have been supported by the work of 
many researchers, whether Aβ accumulation is the prime event in the development of AD 
neuropathological processes is still not clearly established 
34–38
. Furthermore, soluble forms of 
Aβ, i.e. the precursors that subsequently lead to Aβ plaques, might be more toxic than the 
aggregated insoluble forms: oligomeric neurotoxic species of Aβ bind to different 
components of neuronal and non-neuronal plasma membranes, and induce complex patterns 
of synaptic dysfunction and synapse loss 
23
. 
The striking role of the sleep-wake cycle in the unfolding of Aβ pathology finds its 
roots in two landmark findings: the discovery that soluble Aβ dynamics are strongly 
associated with sleep and wakefulness 
39,40
, and the existence of a sleep-related metabolite 
clearance system in the brain 
41,42
. Using in vivo microdialysis, Kang and colleagues
39
 
investigated hippocampal Aβ levels during wakefulness and sleep in wild-type mice and 
Tg2576 mice, a well-characterized mouse model of AD known to overexpress a mutant form 
of human APP 
43,44
. First, they found that interstitial fluid (ISF) Aβ levels of Tg2576 mice 
exhibit a diurnal variation, with a significant decrease of approximately 25% during the light 
period (i.e. when mice sleep most) relative to the dark period. Crucially, they observed that 
the same pattern of variation is also present in the ISF of wild-type mice and in the CSF of 
young healthy humans, indicating that Aβ fluctuation over a 24h-period is inherent to normal 
cellular physiology. Furthermore, sleep-deprived mice showed significantly increased Aβ 
levels that were promptly reduced after sleep recovery. In order to unravel the underlying 
molecular mechanisms, the potential role of orexin, a peptide promoting arousal and 
wakefulness 
45–47




















during the light period while an orexin receptor antagonist abolished the previously observed 
diurnal variation. At a broader level, chronic sleep restriction in mice (20 hours daily for 21 
days) was associated with greater Aβ plaque burden among several brain regions, whereas 
enhancing sleep via chronic orexin antagonist treatment (once daily for 8 weeks) was related 
to reduced Aβ plaque deposition. 
The characterization of the sleep-wake modulation of Aβ dynamics was further 
expanded to include a recently described process of brain cellular waste regulation, called the 
‘glymphatic system’ 42,48. This system consists in convective fluxes from the para-arterial CSF 
through ISF and toward the para-venous space that allow neuronal products to be transported 
to the systemic circulation for clearance 
48,49
. The glymphatic process can be altered by 
genetic variations affecting aquaporin 4 water channels 
50
 and has been linked to AD and 
other dementias 
51
. Using two-photon imaging of the brain of living adult mice, Xie et al.
42
 
found that the glymphatic system is strongly regulated by the sleep-wake cycle. They 
observed that the CSF influx was highly increased in the brain of sleeping and anesthetized 
mice compared to awake littermates. In turn, the larger CSF influx led to a more efficient 
glymphatic clearance, as illustrated by a rate of interstitial Aβ removal up to twice as fast in 
sleeping mice. Interestingly, the authors found that the volume of the interstitial space was 
over 60% greater when mice were sleeping or anesthetized, thus allowing easier CSF 
movement and, therefore, more efficient glymphatic clearance of neuronal by-products such 
as Aβ. Moreover, elevated Aβ levels as a consequence of sleep deprivation have been 
observed in CSF samples both in humans 
52
 and in adult rats 
53
. One night of sleep deprivation 
also appeared to significantly increase PET Aβ plaque burden in the hippocampus and the 
thalamus in humans 
54
, although it is unclear how acute sleep deprivation may affect short-




















It seems that slow wave sleep (SWS; or ‘deep sleep’, dominated by large amplitude 
and low frequency EEG oscillations 
55
) is a key component of the association between sleep-
wake regulation and Aβ aggregation. The release of soluble Aβ in the interstitial space was 
shown to depend on endogenous neuronal activity, with extended wakefulness leading to an 
overall increase in neuronal firing and thus to elevated Aβ levels 56–58. In addition, slow wave 
activity (SWA; a quantification of sleep slow waves during sleep) in frontal regions was 
associated with higher CSF Aβ42 levels in cognitively normal older individuals 59. Finally, a 
recent study showed that specific disruption of SWS during one night induced higher levels of 
CSF Aβ40 on the following morning 60. Altogether, these results suggest that reduction of 
SWS may lead to a relative augmentation in neuronal activity during sleep that, in turn, 
increases the production of Aβ and/or reduces the effectiveness of its clearance. Recent 
evidence shows that Aβ concentration in the CSF increases following sleep deprivation while 
it does not decrease when attempting to enhance SWS, which may suggest that altered Aβ 
production, rather than its clearance, underlies the link between altered sleep and Aβ levels 61. 
It remains to be determined whether the well-established modification in sleep structure in 
older people, including a significant reduction of SWS duration 
62,63
, contributes to or is, in 
part, a consequence of the age-related increase in Aβ burden in healthy individuals 64. 
The depicted relationship between sleep-wake disruption and Aβ deposition is indeed 
most likely bidirectional 
65–67
. Albeit we emphasized that sleep-wake disorganization 
accelerates Aβ accumulation, it seems that Aβ deposits conversely impede sleep-wake 
regulation. A transgenic APP mouse model showed changes in the sleep-wake cycle that 
closely followed the emergence of Aβ plaques, and the intensity of these changes correlated 
with the extent of Aβ deposits 58. Interestingly, active Aβ immunization prevented these 




















sleep-wake regulation. Likewise, Aβ accumulation impaired slow waves propagation during 
sleep in AD mice whereas exogenous Aβ infusion disrupted SWA in wild-type mice until 
wash-out 
68
. In a Drosophila model of AD including human APP and beta-secretase cleaving 
enzyme expression, sleep is significantly disrupted when these proteins are co-expressed 
69
. 
Many other associations between sleep-wake regulation and Aβ are described below. 
We stress, however, that it is unclear whether these associations result from a causal impact of 
sleep-wake dysfunction or whether the latter may be a consequence of abnormal presence of 
Aβ. For instance, several studies showed that self-reported sleep quality is associated with Aβ 
deposition measured with PET and CSF markers in healthy older individuals 
28,70–72
. In two 
longitudinal studies, self-reported excessive daytime sleepiness at baseline was linked to 
increased accumulation of Aβ over 7 and 15.7 years in cognitively normal older individuals 
73,74
. Self-reported sleep latency was also associated with brain Aβ deposition in a well-
characterized cohort of older men and women 
72,75
, while poor self-reported sleep history was 
associated with increased Aβ burden in the hippocampus and the thalamus 54. Objective 
measures of sleep efficiency, based on actigraphic recordings, were also linked to abnormal 
levels of amyloid in the CSF in healthy older adults 
76
. Likewise, an association was reported 
between PET Aβ pathology in the medial prefrontal cortex and slow waves generation 77. 
Obstructive sleep apnea (OSA), a well-established sleep disruption factor associated with a 
higher risk of developing cognitive impairments and AD 
78
, has been linked to increased CSF 
and PET Aβ burden in cognitively normal older adults 79,80. One hypothesis is that glymphatic 
clearance processes are altered by mechanical changes during respiratory efforts in OSA 
patients, thus promoting protein accumulation 
78,81
. Finally, rest-activity rhythm 
fragmentation, objectively estimated by actigraphic measures, has recently been associated 






















. This relationship remained significant after adjusting for age, implying that 
aging and preclinical Aβ pathology likely have separate contributions on sleep-wake 
disturbances. 
Crucially, the interaction between worse sleep efficiency and abnormal CSF amyloid 
levels may account for worse memory function in the preclinical stages of AD 
83
. This could 
mean that beyond the respective negative impact of poor sleep-wake quality 
84
 and of Aβ 
burden 
85
 on cognitive function, there may be an interaction effect that would lead to a 
multiplicative impact of both, at least when exceeding a certain threshold. However, isolating 
their respective contributions on cognition may constitute a difficult challenge since they are 
both changing importantly in aging. 
The numerous findings reviewed here make a strong case for the bidirectional link 
between sleep-wake regulation and Aβ deposition. Interestingly, low-dose benzodiazepine 
administration to AD mice improved SWS and cognition, suggesting a potential role for γ-
aminobutyric acid inhibition to alleviate part of Aβ negative impact through sleep 68. It is 
unknown, however, whether acting on Aβ per se and reducing its burden would result in an 
improved sleep-wake regulation. Likewise, no studies have yet attempted to act on sleep-
wake quality to reduce Aβ burden or to slow down its increase. 
   [INSERT TABLE 1 about here] 
Sleep-wake regulation and tau 
 Tau is a microtubule-associated protein whose primary role is to maintain the stability 
of the axonal cytoskeleton 
86
. In the course of several neurodegenerative diseases, including 
AD, tau undergoes abnormal hyperphosphorylation, oligomerization then conversion into 
insoluble filamentous state 
87,88




















tau assembles into toxic oligomers which eventually form intracellular NFTs 
89
. Whether 
these NFTs are toxic or not remains debated 
90
, as they may not impede normal neuronal 
function once released in the extracellular space upon neuron death 
91
. As for Aβ, the AD-
related pathophysiological process of tau follows a stereotyped progression pattern 
92
. As 
early as in the first decades of life, hyperphosphorylated tau can be found in the brainstem 
locus cœruleus and other subcortical nuclei 64,93, which are keys sites in sleep-wake regulation 
94
. During the preclinical stages of AD, tau pathology is observed in the medial temporal lobe, 
and further spreads to the neocortex as the disease progresses 
95–97
. Interestingly, abnormal 
levels of tau protein in the CSF in preclinical AD constitute an accurate proxy measure of tau 




Critically, Yamada et al. 
99
 demonstrated using in vivo microdialysis in wild-type mice 
that increasing neuronal activity significantly elevated ISF tau levels within hours. Similar to 
Aβ regulation processes, this indicates that a relative increase in neuronal activity, as 
observed during extended wakefulness or chronic sleep restriction, could lead to an increase 
in extracellular tau production that would ultimately be reflected in CSF measures. However, 
tau is a relatively stable protein with a slow turnover rate, so that around 11 days are required 
before CSF changes can be observed 
99,100
. This may explain why, contrary to Aβ, one night 
of acute sleep disruption could not be linked to an increase in CSF tau levels assessed on the 
subsequent morning in humans 
52,60
. In fact, worse home sleep quality measured with 
actigraphic recordings during the week preceding in-lab sleep disruption was positively 
associated with higher CSF tau levels 
60
. In mouse models with plaques and tangles 
pathology, restricting sleep to 4 hours per day for 8 weeks 
101
, or to 6 hours per day for 6 
weeks 
102




















cohort study found that actigraphic measures of better sleep consolidation in older individuals 
significantly attenuated the effect of APOE genotype on observed NFTs density at autopsy 
103
. 
As for Aβ, the link between sleep-wake regulation and tau is likely bidirectional. A 
longitudinal study in cognitively normal older individuals showed that higher CSF tau levels 
were predictive of overall poorer sleep quality after 3 years 
104
. However, this association was 
only present in individuals with significant Aβ deposition, further supporting the deleterious 
nature of tau and Aβ co-existence 105. In addition, a human tau and amyloid knock-in mouse 
model of AD exhibits increased wake bout duration combined with decreased rapid eye 
movement (REM) and non-REM sleep duration 
106,107
. Transgenic mice expressing tau 
without Aβ abnormal accumulation display similar sleep-wake alterations, suggesting that tau 
pathology alone can induce impaired sleep and wakefulness in such animal models 
108
. Of 
particular interest, the extent of the observed sleep impairments correlated with tau pathology 
intensity in brainstem regions regulating sleep 
109
. Likewise, progressive supranuclear palsy, a 
tau only form of frontotemporal dementia that mainly involves brainstem and thalamic 
regions, was associated with more fragmented sleep and increased daytime sleepiness 
110,111
, 
further suggesting a causal role for abnormal tau aggregation and sleep dysfunction.  
Again similar to Aβ, many other associations between tau pathology and sleep-wake 
regulation have been reported, but it is difficult to identify the directionality of their interplay. 
In young and middle-aged individuals, OSA has been associated with elevated levels of tau 
protein concentration in blood 
112,113
. However, a recent study did not find any significant 
association between tau burden measured with PET and sleep disordered breathing in a cohort 
of 119 older males 
79
. In cognitively normal older people, CSF levels of phosphorylated tau 
were positively correlated with an increase in orexin concentration, potentially because 
elevated orexin levels favor fragmented sleep 
114






















Akin to Aβ, both objective and subjective measures of sleep quality (respectively, sleep 
efficiency derived from actigraphic recordings, and multidimensional self-reported scales) 
have been associated with elevated CSF tau levels 
28,60
. Finally, the fragmentation of the 
circadian rhythmicity of sleep and wakefulness positively correlates with the ratio between 




Although convincingly demonstrated, the proofs of the bidirectionality of the link 
between tau pathology and sleep-wake regulation are less numerous than for Aβ. This 
probably resides in part in the absence of in vivo radiotracer for tau until very recently 
118,119
, 
implying that one could only rely on CSF measure to infer tau burden in vivo. While the first 
PET markers suffered from relative unspecific bindings, the new generation seems to be 
particularly specific to tau 
120
, such that our understanding of the association between tau and 
the sleep-wake cycle is likely to grow swiftly. 
Critically, chronic sleep-wake disruption was consistently associated with tau 
phosphorylation changes and long-lasting memory deficits not only in AD mouse models, but 
also in wild-type littermates 
121
. This suggests that recurrent sleep deprivation plays a 
significant role in tau-related measures as well as cognitive outcomes, beyond at least some 
genetic AD predispositions. Whether improving sleep-wake quality would reduce tau burden, 
or slow down its progression to then improve cognition, has however not been tested yet. 
Likewise, no attempt has been made until now to address whether pharmacologically reducing 
tau burden would improve cognition via an enhancement of sleep-wake quality. 
   [INSERT TABLE 2 about here] 




















Synaptic and neuronal loss represents one of the strongest pathological correlates of 
dementia 
14,122
, and a reliable predictor of conversion from MCI to AD 
123–125
. 
Neurodegeneration of the medial temporal lobe can be detected up to 4 years before the 
clinical diagnosis of AD, and correlates with tau deposition as well as early memory deficits 
126,127
. The dynamic of brain atrophy mirrors the propagation of NFTs in early stages, then 
neuronal loss is progressively observed in temporo-parietal cortices, and ultimately in frontal 
regions 
128
. In asymptomatic individuals, it was suggested that baseline rates of brain atrophy 
are accelerated in those that further transition to MCI 
129
. Although no magnetic resonance 
imaging (MRI) marker has been proved efficient to identify alone the preclinical stages of the 
disease, recent combinations of neuroimaging techniques hold strong potential for early 
detection of preclinical AD 
130
. 
As for tau and Aβ burden, sleep-wake regulation is associated with neurodegeneration. 
In young adults, sleep continuity and sleep duration were associated with brain white matter 
integrity, based on measures of mean diffusivity derived from diffusion-weighted imaging 
131
. 
In healthy older individuals, self-reported excessive daytime sleepiness and fatigue were 
associated to MRI measures of global and regional atrophy, as well as hippocampal volume 
reduction 
132
. Similarly, MRI based cortical thinning of several brain areas was linked to an 
age-related decrease in slow wave density and amplitude, based on electroencephalographic 
measures during sleep 
133
. In addition, reduction of REM sleep duration in MCI subjects was 
associated with grey matter loss in regions that are affected early in AD, such as the 
precuneus, the posterior cingulate, and the postcentral gyrus 
134
. Likewise, actigraphic 
assessment of sleep-wake rhythm fragmentation was related to the atrophy of the medial 
temporal lobe measured by expert visual evaluation (use of visual scale, i.e. no computerized 






















In cognitively normal older individuals, sleep durations shorter or longer than 7 hours 
have been associated with higher rates of frontotemporal grey matter decline in longitudinal 
assessments over 8 years 
136
. Others found that short sleep duration similarly affects the 
expansion rates of the ventricles 
137
. Moreover, self-reported sleep quality indices correlated 
with the rate of cortical atrophy measured over an average of 3.5 years, in a widespread set of 
frontal, temporal and parietal areas 
138
. These longitudinal data suggest that sleep quality 
directly affects cortical atrophy. This view is further reinforced by the report of decreased 
neuron density in the locus cœruleus after extended wakefulness in wild-type mice 139. 
Critically, chronic sleep restriction in mice lead to neuronal loss in the locus cœruleus that 
could not be compensated for after a 6-month recovery period in normal sleep conditions 
140
. 
Normal aging is also associated with structural changes in sleep-wake regulating 
structures 
141
. The locus cœruleus shows a limited decline in neuron number with age and 
undergoes a marked reduction in the number of its projections to the cortex and particularly to 
the prefrontal cortex 
6,142
. The basal forebrain, and especially the cholinergic neurons of the 
nucleus of Meynert 
143
, the suprachiasmatic nucleus corresponding to the master circadian 
clock 
144
, or the lateral hypothalamus secreting orexin and melanin-concentrating hormone 
145
, 
also undergo a decrease in neuron and/or axonal density in aging. These deficits are further 
aggravated in AD 
146–148
. However, the functional consequences of the changes in sleep-wake 
regulating subcortical structures are mostly unassessed. It is therefore unclear whether they 
directly contribute to the well-characterized degradation in sleep quality and sleep-wake 
regulation associated with aging 
149
. 
Hence, age-related neurodegeneration must undoubtedly contributes to changes in 
sleep and in wakefulness, but direct evidence remains scarce. How neurodegeneration 




















dysfunction affects AD through neurodegeneration is not known. Addressing these issues is 
complicated notably because quantifying changes in brain structure in vivo is far from trivial. 
While the first demonstrations of age-related changes in MRI data were interpreted as 
indications of neurodegeneration, recent research showed that these changes may reflect 
modifications in neuronal iron or axonal myelin content rather than reflecting a mere loss of 
neurons 
150,151
. Crucially, the development of unbiased quantitative MRI 
152
 will provide 
important tools to address the link between sleep-wake quality and brain structure and 
microstructure. 
   [INSERT TABLE 3 about here] 
Conclusions 
 We reviewed findings indicating that disruption of sleep-wake regulation is linked to 
the hallmarks of AD pathogenesis in the preclinical stages of the disease, that is, many years 
before the cognitive symptoms emerge. Evidence for bidirectional relationships between 
sleep-wake regulation and the three hallmarks of AD pathophysiology has accumulated, albeit 
more convincingly with Aβ. Recent technical developments in MRI and PET in vivo measures 
of brain structure will hel  establishing these relationships 
130
. Yet, research is still limited by 
the sensitivity of current techniques. Indeed, PET imaging does not allow to quantify the 
earliest tau (e.g. in the brainstem) or Aβ deposits. Besides, soluble forms of misfolded Aβ and 
tau proteins may be more involved in AD progression and neuronal death compared with their 
aggregates 
23,153
. However, these soluble forms remain mostly undetectable in vivo and their 
impact on sleep-wake regulation is unknown. One could also consider that the locations of 
protein aggregates and of their soluble precursors is important, but this remains largely 
unexplored (see Mander et al. 
77





















The large time-window of AD pathophysiological progression is a great opportunity 
for preventive interventions. However, it also means that curative or preventive interventions 
may be applied too late in the process to be efficient, i.e. when irreversible damage has 
occurred 
1
. Thus, the earliest aspects associated with AD pathogenesis need to be established. 
Factors related to sleep-wake regulation are, in our view, excellent candidates based on the 
findings reviewed here, but also given the fact that the first signs of tau deposition are 
detected, post mortem, in the locus cœruleus. However, these first deposits are undetectable in 
vivo, and their functional consequences are unknown 
6
. In addition, tau accumulation may 
primarily represents age-related modifications, i.e. brain changes that are normal over the 
lifespan 
154
. This does not preclude these protein accumulations, variable across individuals 
64
, 
to contribute to the observed variability in age-related changes in sleep-wake regulation, or to 
be caused by the latter variability. It is therefore highly needed, and yet highly challenging, to 
separate what constitutes normal neurodegeneration, protein accumulations, and sleep-wake 
changes from what will contribute to AD pathology decades later. 
The definite proofs that improving sleep and wakefulness in the preclinical stages of 
the disease causally slows down the AD neuropathological processes over decades still need 
to be provided. Conversely, whether hindering tau and Aβ accumulation as well as 
neurodegeneration may improve sleep has to be demonstrated. Longitudinal studies in 
interventional designs are of particular interest to provide these proofs, but they may not be 
available before long. Even in the absence of such evidence, one could consider applying 
cognitive behavioral therapy 
155
 or increasing the amplitude of the rest-activity cycle with 
light 
156
 and/or physical activity 
157
 to modulate AD neuropathological processes through 
improved sleep and wakefulness quality. Given the high prevalence of sleep-wake complaints 




















improve brain function in the short term, and to decrease the odds of developing AD, 
particularly in those individuals that are more at risk. 
 
List of Abbreviations: AD = Alzheimer’s disease; Aβ = Amyloid-beta; NFTs = Neurofibrillary 
tangles; MCI = Mild cognitive impairment; APOE = Apolipoprotein E; APP = Amyloid precursor 
protein; PET = Positron emission tomography; CSF = Cerebrospinal fluid; ISF = Interstitial fluid; 
SWS = Slow wave sleep; SWA = Slow wave activity; REM = Rapid eye movement; MRI = Magnetic 
resonance imaging 
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Table 1. Summary table of studies considered in this review and directly linking sleep-wake regulation to amyloid-beta. 
Reference Target population (N, age) Sleep-wake variable(s) Aβ variable(s) Main outcome(s) 
Branger et al., 2016 Cognitively normal 
participants (51, 64.1 ± 10.6 
years) 
Self-reported sleep latency 
and sleep quality 
Cortex Aβ burden Longer sleep latency and 
poorer sleep quality were 
associated with increased 
Aβ burden. 
Brown et al., 2016 Cognitively normal 
participants (184, 75.5 ± 6.1 
years) 
Sleep latency Cortex Aβ burden Longer sleep latency was 
associated with increased 
Aβ burden. 
Busche et al., 2015 APP23xPS45 mice (5, 6-8 
months), wild-type mice (6, 
6-8 months) 
 
Long-range SWA coherence Cortex, hippocampus, and 
thalamus Aβ burden, 
exogenous Aβ infusion 
SWA coherence between 
cortex and hippocampus 
was disrupted in transgenic 
mice. 
Aβ administration was 
associated with impaired 
SWA coherence in wild-
type mice. 
Carvalho et al., 2018 Cognitively normal 
participants (283, 77.1 ± 4.8 
years) 
ESS Longitudinal Aβ 
accumulation 
Excessive daytime 
sleepiness was associated 
with increased Aβ 





















Chen et al., 2017 Male Sprague-Dawley rats 
(40, 3 months) 
2-4 days of paradoxical 
sleep deprivation 
Hippocampus Aβ burden Acute sleep deprivation was 
associated with increased 
Aβ burden 
Dissel et al., 2017 Adult UAS-APP:BACE 
flies (30, 7 days) 
Sleep latency, sleep 
fragmentation, sleep 
duration 
Human APP and BACE co-
expression 
Co-expression of APP and 
BACE was associated with 
reduced sleep duration and 
increased sleep 
fragmentation. 
Elias et al., 2018 Male cognitively normal 
OSA patients (42, 67.69 ± 
5.37 years) and controls (77, 
68.3 ± 3.86 years) 
Apnea-hypopnea index Cortex Aβ burden Aβ burden was increased in 
OSA patients compared to 
controls. 
Ju et al., 2013 Cognitively normal 
participants (142, 65.6 ± 8.2 
years) 
2 weeks of at-home 
actigraphic recording 
CSF-Aβ level Worse sleep efficiency was 
associated with abnormal 
CSF-Aβ level. 
Ju et al., 2016 Cognitively normal OSA 
patients (10, 48-62) and 




CSF-Aβ level Reduced NREM SWA was 
associated with increased 
CSF-Aβ level in controls. 
Higher apnea-hypopnea 
index was associated with 




















Ju et al., 2017 Cognitively normal 
participants (14, 35-65 
years) 
1 night of specific SWA 
disruption 
CSF-Aβ level Specific SWA disruption 
was associated with higher 
CSF-Aβ level. 
Kang et al., 2009 Tg2576 mice (16, 3-9.5 
months), C57BL6/SJL mice 





 mice (38, 
1.7-3.5 months) 
Male cognitively normal 
participants (10, 20-50 
years) 
Acute sleep deprivation, 
sleep restriction to 4h/day 
for 3 weeks, almorexant 
injection (1/day for 8 
weeks) 
ISF-Aβ level,  
CSF-Aβ level, cortex and 
hippocampus Aβ burden 
ISF- and CSF-Aβ levels 
showed fluctuations over a 
24h-period. 
Acute and chronic sleep 
deprivation were associated 
with increased ISF-Aβ level 
and increased Aβ burden, 
respectively.  
Chronic almorexant 
injection was associated 
with reduced Aβ burden. 
Lucey et al., 2018 Cognitively normal 
participants (8, 30-60 years) 
1 night of sleep deprivation, 
1 night of SWS 
augmentation 
CSF-Aβ level Total sleep deprivation was 
associated with increased 
CSF-Aβ level. 
No association between 
SWS augmentation and 
CSF-Aβ level. 
Mander et al., 2015 Cognitively normal 
participants (26, 75.1 ± 8.2 
years) 
NREM SWA Medial prefrontal cortex Aβ 
burden 
Increased Aβ burden was 





















Molano et al., 2017 Cognitively normal 
participants (98, 69 ± 7.1 
years 
2 weeks of at-home 
actigraphic recording 
CSF-Aβ level The interaction between 
worse sleep efficiency and 
abnormal CSF-Aβ level was 
associated with poorer 
cognition. 
Musiek et al., 2018 Cognitively normal 
participants (148, 66.6 ± 8.3 
years) 
1 week of at-home 
actigraphy 
Cortex Aβ burden Higher fragmentation of 
rest-activity circadian 
rhythm was associated with 
increased Aβ burden. 
Ooms et al., 2014 Male cognitively normal 
participants (26, 40-60 
years) 
1 night of total sleep 
deprivation 
CSF-Aβ level Total sleep deprivation was 
associated with increased 
CSF-Aβ level. 




 mice (32, 3-
9 months) 
Wakefulness duration, 
NREM/REM sleep duration  
Hippocampus Aβ burden, 
active immunization to Aβ 
Increased Aβ burden was 
associated with increased 
wakefulness duration and 
decreased NREM/REM 
duration.  
Active immunization to Aβ 




























(12, 3-6 months), APP/PS1-
21/OR
-/-
 mice (12, 3.5-8.5 
months)  
Orexin modulation, sleep 
restriction to 4h/day for 3 
weeks 
Cortex and hippocampus Aβ 
burden 
Transgenic orexin knockout 
mice displayed decreased 
Aβ burden and increased 
sleep duration. 
Chronic sleep restriction 
was associated with 
increased Aβ burden. 
Sharma et al., 2018 Cognitively normal OSA 
patients (111, 69.26 ± 7.41 
years) and controls (97, 
67.56 ± 7.32 years) 




index was associated with 
abnormal CSF-Aβ level and 
increased Aβ accumulation 
over 2 years of follow-up. 
Shokri-Kojori et al., 2017 Cognitively normal 
participants (24, 22-72 
years) 
1 night of total sleep 
deprivation, self-reported 
sleep history 
Hippocampus and thalamus 
Aβ burden 
Total sleep deprivation and 
poorer self-reported sleep 
history were associated with 
increased Aβ burden. 
Spira et al., 2013 Cognitively normal 
participants (70, 53-91 
years) 
Self-reported sleep duration 
and sleep quality 
Cortex and precuneus Aβ 
burden 
Poorer sleep quality and 
shorter sleep duration were 
associated with increased 
Aβ burden. 
Spira et al., 2018 Cognitively normal 
participants (123, 36.2-82.7 
years) 
Self-reported excessive 





sleepiness was associated 




















over 15.7 years follow-up.  
No association between 
napping and Aβ burden. 
Sprecher et al., 2015 Cognitively normal 
participants (98, 50-73 
years) 
ESS, MOS Cortex Aβ burden Greater somnolence and 
sleep disturbances were 
associated with increased 
Aβ burden. 
Sprecher et al., 2017 Cognitively normal 
participants (101, 62.9 ± 6.2 
years) 
MOS, ESS CSF-Aβ level Poorer sleep quality, greater 
sleep disturbance and 
daytime somnolence were 
associated with abnormal 
CSF-Aβ level. 
Varga et al., 2016 Cognitively normal 
participants (36, 66.8 ± 8.2 
years) 
SWA, SWS duration CSF-Aβ level Reduced SWA and SWS 
duration were associated 
with higher CSF-Aβ level. 
Xie et al., 2013 C57BL6 mice (12, 3 
months) 
Natural and induced sleep Aβ glymphatic clearance 
rate 
Natural and induced sleep 
were associated with a 60% 
increase in interstitial space 
volume, resulting in easier 
glymphatic clearance. 
Abbreviations: Aβ = Amyloid-beta; APP = amyloid precursor protein; BACE = Beta-secretase cleaving enzyme; CSF = Cerebrospinal fluid; ESS = 
Epworth sleepiness scale; ISF = Interstitial fluid; MOS = Medical outcomes study sleep scale; NREM = Non-rapid eye movement; OSA = Obstructive 




















Table 2. Summary table of studies considered in this review and directly linking sleep-wake regulation to tau. 
Reference Target population (N, age) Sleep-wake variable(s) Tau variable(s) Main outcome(s) 
Arnulf et al., 2005 PSP patients (15, 68 ± 8 
years) and cognitively 
normal controls (15, 67 ± 10 
years) 
Sleep fragmentation, REM 
sleep without atonia, RBD 
Brain tau accumulation 
without abnormal Aβ 
burden 
Higher sleep fragmentation, 
longer REM sleep without 
atonia duration, and RBD in 
PSP patients compared to 
controls. 
Bu et al., 2015 Cognitively normal OSA 
patients (45, 44.31 ± 9.96 
years) 
Apnea-hypopnea index Serum tau level Higher apnea-hypopnea 
index was associated with 
higher serum tau level. 
Di Meco et al., 2014 Male 3xTG mice (18, 10 
months) 
Sleep restriction to 4h/day 
for 8 weeks 
Brain insoluble tau burden Chronic sleep restriction 
was associated with 
increased insoluble tau 
level. 
Elias et al., 2018 Male cognitively normal 
OSA patients (42, 67.69 ± 
5.37 years) and controls (77, 
68.3 ± 3.86 years) 
Apnea-hypopnea index Cortex tau burden No difference in tau burden 
in OSA patients compared 
to controls. 
Fjell et al., 2017 Cognitively normal 
participants (91, 64-89 
years) 
PSQI CSF-tau level Higher CSF-tau level was 
predictive of worse sleep 





















Holth et al., 2017 Male P301S mice (40, 3-12 
months) 
Wake bout duration, 
NREM/REM sleep duration 
Brainstem tau burden Higher brainstem tau burden 
was associated with 
increased wakefulness, 
decreased NREM and REM 
sleep duration. 
Ju et al., 2017 Cognitively normal 
participants (14, 35-65 
years) 
1 week of at-home 
actigraphic recording, 1 
night of specific SWA 
disruption 
CSF-tau level No association between 
SWA disruption and CSF-
tau level. 
Better home sleep quality 
was associated with lower 
CSF-tau level. 
Jyoti et al., 2015 PLB1triple mice (14, 5-21 
months) 
Wake bout duration, 
NREM/REM sleep duration 
Cortex and hippocampus tau 
burden 
Tau burden was associated 
with increased wakefulness, 
and reduced NREM and 
REM sleep duration. 
Lim et al., 2013 Cognitively normal 
participants (201, 85.9 ± 6.3 
years) 
10 days of actigraphic 
recordings 
Brain NFTs density at 
autopsy 
Better sleep consolidation 
was associated with 
decreased NFTs density. 
Motamedi et al., 2017 Cognitively normal OSA 
patients (50, 34.9 ± 8 years) 
Apnea-hypopnea index Plasma tau level Higher apnea-hypopnea 
index was associated with 




















Musiek et al., 2018 Cognitively normal 
participants (148, 66.6 ± 
8.3) 
1 week of at home 
actigraphy 
CSF-tau level Higher fragmentation of 
rest-activity circadian 
rhythm was associated with 
higher CSF-tau level. 
Ooms et al., 2014  Cognitively normal men 
(26, 40-60 years) 
1 night of total sleep 
deprivation 
CSF-tau level No association between total 
sleep deprivation and CSF-
tau level. 
Osorio et al., 2016 Cognitively normal 
participants (63, 69.59 ± 
8.55 years) 
CSF-orexin level CSF-tau levels Higher CSF-orexin level 
was associated with higher 
CSF-tau levels. 
Platt et al., 2011 PLB1triple mice (11, 5-12 
months) 
Wake bout duration, NREM 
sleep duration 
Cortex and hippocampus tau 
burden 
Tau burden was associated 
with increased wakefulness 
and reduced NREM sleep 
duration. 




 mice (40, 4-
10 months), wild-type 
littermates (40, 4-10 
months) 
Sleep restriction to 4h/day 
for 8 weeks 
Frontal cortex and 
hippocampus tau burden 
Chronic sleep deprivation 
was associated with long-
lasting increased tau burden 
in both transgenic and wild-
type mice. 
Rothman et al., 2013 Male 3xTG mice (10, 14 
months) 
Sleep restriction to 6h/day 
for 6 weeks 
Cortex and hippocampus tau 
burden 
Chronic sleep restriction 
was associated with 





















Sprecher et al., 2017 Cognitively normal 
participants (101, 62.9 ± 6.2 
years) 
MOS, ESS CSF-tau level Higher excessive daytime 
sleepiness and worse 
subjective sleep quality 
were associated with higher 
CSF-tau level. 
Stevanovic et al., 2017 Tg4510 mice (11, 8-13 
months) 
Rest-activity circadian 
rhythm, clock gene 
(BMAL1, PER2) expression 
SCN and hippocampus tau 
burden 
Tau burden was associated 
with altered SCN circadian 
outputs and clock protein 
(PER2) rhythm in the 
hippocampus. 
Walsh et al., 2017 PSP patients (19, 70.94 ± 
5.3 years) and cognitively 
normal controls (16, 72.50 ± 
1 years) 




Brain tau accumulation 
without abnormal Aβ 
burden 
Longer sleep latency, lower 
sleep duration, higher sleep 
fragmentation, and higher 
subjective sleepiness were 
found in PSP patients 
compared to controls. 
Abbreviations: Aβ = Amyloid-beta; CSF = Cerebrospinal fluid; ESS = Epworth sleepiness scale; MOS = Medical outcomes study sleep scale; NFTs = 
Neurofibrillary tangles; NREM = Non-rapid eye movement; OSA = Obstructive sleep apnea; PSQI = Pittsburgh sleep quality index; RBD = Rapid eye 





















Table 3. Summary table of studies considered in this review and directly linking sleep-wake regulation to neurodegeneration. 




Carvalho et al., 2017 Cognitively normal 
participants (1374, 72.16 ± 
8.8 years) 
ESS, fatigue Grey matter integrity Higher excessive daytime 
sleepiness and fatigue were 
associated with lower 
cortical thickness. 
Dubé et al., 2015 Cognitively normal 
participants (63, 20-70 
years) 
Sleep slow waves density 
and amplitude 
Grey matter integrity Higher sleep slow waves 
density and amplitude were 
associated with higher grey 
matter integrity in sleep 
slow waves related regions. 
Lo et al., 2014 Cognitively normal 
participants (66, 69.5 ± 5.7 
years) 
Self-reported sleep duration Longitudinal ventricles 
expansion rate 
Reduced sleep duration was 
associated with faster annual 
expansion rates of the 
ventricles over 2 years of 
follow-up. 
Sanchez-Espinosa et al., 
2014 
aMCI participants (21, 69.8 
± 5.5 years) 
REM sleep duration Grey matter integrity Lower REM sleep duration 
was associated with reduced 
grey matter integrity in 
brain regions involved in 




















Sexton et al., 2014 Cognitively normal 
participants (147, 20.4-84.2 
years) 
PSQI Longitudinal grey matter 
decline 
Worse sleep quality was 
associated with higher rates 
of grey matter atrophy over 
3.5 years of follow-up. 
Spira et al., 2016 Cognitively normal 
participants (122, 51-86 
years) 
Self-reported sleep duration Longitudinal grey matter 
decline 
Sleep durations of less or 
more than 7 hours were 
associated with higher rates 
of grey matter atrophy over 
8 years of follow-up. 
Takeuchi et al., 2018 Cognitively normal 
participants (1201, 18-27 
years)  
Self-reported sleep 
continuity and sleep 
duration 
White matter integrity Higher sleep continuity and 
lower sleep duration were 
associated with higher white 
matter integrity. 
Van Someren et al., 2018 Cognitively normal 
participants (138, 69.1 ± 8.5 
years) 
1 week of at home 
actigraphic recording 
Medial temporal lobe 
atrophy 
Higher fragmentation of 
rest-activity circadian 
rhythm was associated with 
higher medial temporal lobe 
atrophy. 
Zhang et al., 2014 Male SirT3 wild-type mice 
(5, 2 months) 
Sleep restriction to 4h/day  Number of locus coeruleus 
neurons  
Extended wakefulness was 
associated with a loss of 





















Zhu et al., 2007 Male C57BL/6J mice (10, 2 
months) 
Long-term intermittent 
hypoxia exposure for 8 
weeks, sleep duration, sleep 
latency  
Number of locus coeruleus 
neurons. 
Chronic sleep disruption 
was associated with a loss of 
neurons in the locus 
coeruleus that had long-
lasting effects on sleep 
duration and sleep latency.  
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